logo
The AI boom's hidden risk to the economy

The AI boom's hidden risk to the economy

Mint2 days ago
In the past two weeks one big tech company after another reported blowout earnings amid a wholesale embrace of artificial intelligence.
Look a little closer, and a more unsettling side to the AI boom emerges. All the spending on chips, data centers and other AI infrastructure is draining American corporations of cash.
This underscores the hidden risks from the AI boom. No one doubts its potential to raise growth and productivity in the long run. But financing that boom is straining the companies and capital markets.
Since the first quarter of 2023, investment in information processing equipment has expanded 23%, after inflation, while total gross domestic product has expanded just 6%. In the first half of the year, information processing investment contributed more than half the sluggish 1.2% overall growth rate. In effect, AI spending propped up the economy while consumer spending stagnated.
Much of that investment consists of the graphics-processing units, memory chips, servers, and networking gear to train and run the large language models at the heart of the boom. And all that computing power needs buildings, land and power generation.
This is transforming big tech's business models.
For years, investors loved those models because they were 'asset-light." They earned their profits on intangible assets such as intellectual property, software, and digital platforms with 'network effects." Users flocked to Facebook, Google, the iPhone, and Windows because other users did. Adding revenue required little in the way of more buildings and equipment, making them cash-generating machines.
This can be seen in a metric called free cash flow, roughly defined as cash flow from operations minus capital expenditures. It excludes things such as noncash impairment charges that can distort net income. This is arguably the purest measure of a business's underlying cash-generating potential. Amazon, for example, tells investors: 'Our financial focus is on long-term, sustainable growth in free cash flow."
From 2016 through 2023, free cash flow and net earnings of Alphabet, Amazon, Meta and Microsoft grew roughly in tandem. But since 2023, the two have diverged. The four companies' combined net income is up 73%, to $91 billion, in the second quarter from two years earlier, while free cash flow is down 30% to $40 billion, according to FactSet data. Apple, a relative piker on capital spending, has also seen free cash flow lag behind.
For all of AI's obvious economic potential, the financial return remains a question mark. OpenAI and Anthropic, the two leading stand-alone developers of large language models, though growing fast, are losing money.
Much of big tech companies' latest profits reflect their established franchises: ad spending for Meta and Alphabet, the iPhone for Apple. As to when their AI hardware will pay off, they counsel patience.
Meta, parent of Facebook, reported a 36% rise in earnings for the second quarter, but a 22% drop in free cash flow. It said capital expenditure in 2025 would be roughly double last year's, with 'similarly significant" growth in 2026.
Meta has said much of its AI-related capital spending supports core businesses, such as ads and content, and is already paying off. The balance goes toward generative AI such as its Llama model. 'We are early in the life cycle" of the latter investments, Chief Financial Officer Susan Li told analysts, and 'we don't expect that we are going to be realizing significant revenue from any of those things in the near term."
Amazon began tapering its build-out of fulfillment centers in 2022, allowing free cash flow to turn positive. But in the last year, it has ramped up investment in Amazon Web Services, which hosts data and runs AI models for outside clients, and free cash flow is down by two-thirds from the previous year.
Meta is among the major tech companies making big AI-related capital expenditures.
For now, investors are pricing big tech as if their asset-heavy business will be as profitable as their asset-light models.
So far, 'we don't have any evidence of that," said Jason Thomas, head of research at Carlyle Group. 'The variable people miss out on is the time horizon. All this capital spending may prove productive beyond their wildest dreams, but beyond the relevant time horizon for their shareholders," he added.
In the late 1990s and early 2000s, the nascent internet boom had investors throwing cash at startup web companies and broadband telecommunications carriers. They were right the internet would drive a productivity boom, but wrong about the financial payoff. Many of those companies couldn't earn enough to cover their expenses and went bust. In broadband, excess capacity caused pricing to plunge. The resulting slump in capital spending helped cause a mild recession in 2001.
A dot-com-style bust looks far-fetched now. AI's big spenders are mature and profitable companies, and the demand for computing power exceeds the supply. But if their revenue and profit assumptions prove too optimistic, their current pace of capital spending will be hard to sustain.
Amazon Web Services is spending $11 billion on a data center campus near South Bend, Ind.
After the global financial crisis of 2007-09, big tech was both a beneficiary of low interest rates, and a cause.
Between that crisis and Covid, these companies were generating five to eight times as much cash from operations as they invested, and that spare cash was recycled back into the financial system, Thomas, of Carlyle Group, estimates. It helped hold down long-term interest rates amid high federal deficits, as did inflation below the Federal Reserve's 2% target and the Fed buying bonds. Low interest rates, in turn, made investors value these companies' future profits even more highly.
Today, government deficits are even larger, inflation is above 2% and the Fed has been shrinking its bondholdings. Meanwhile, corporations face steep investment needs to exploit AI and reshore production to avoid tariffs. Thomas estimates that since 2020, their cumulative free cash flow has been 78% lower, relative to GDP, than in the equivalent period following 2009.
All this suggests that interest rates need to be substantially higher in the years ahead than in the years before the pandemic. That is another risk to the economy and these companies that investors may not fully appreciate.
Write to Greg Ip at greg.ip@wsj.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud
FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud

Hindustan Times

timean hour ago

  • Hindustan Times

FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud

MUMBAI: A 65-year-old businessman from Powai lost ₹52 lakh after an allegedly Japanese woman he befriended online convinced him to invest in Bitcoins and duped him in a cybercrime fraud for a month. The West Cyber police had initially received his complaint, and as the defrauded amount was less than ₹1 crore, they forwarded it to the Andheri police station, which registered a case against the woman and her accomplices on Saturday. From the last week of June to July 17, the victim invested ₹ 52 lakh.(HT File Photo) According to the complaint, the businessman received a Facebook friend request from an unknown person in June. The profile had a woman's photo and displayed her employment with IBM in Hong Kong. Believing it to be genuine, the complainant accepted her request, and the two began communicating through the messenger app. Also Read | Senior citizen loses ₹21 lakh to gaming fraud During their conversation, the accused asked for his mobile number, and the two began to speak with each other on the phone. Her soft-spoken manner on calls gained the complainant's trust, he said in the complaint. She told him she was currently working in an IBM office based in Hong Kong and that she would soon be joining the IBM Crypto trading platform in Japan as a manager. The complainant continued to talk with her for 10 more days about various subjects. She would tell him how investing in Bitcoin reaps huge profits and how it could benefit him. Though the complainant was initially reluctant, he was eventually convinced. Also Read | Businessman duped of ₹8.75 crore in a forex trading fraud Once the complainant expressed interest, she sent him a link and asked him to create an ID for his virtual account. He said he began investing money in Bitcoins through the bank accounts she provided. From the last week of June to July 17, he had invested ₹52 lakh. When he checked the application, it displayed ₹10.3 crore as his virtual bank account balance. Noticing huge returns, the 65-year-old wanted to, but could not invest more money in Bitcoins. So, he decided to withdraw the balance accumulated in his account. When he inquired about the withdrawal process, he was asked to pay a 30% tax first. Finding this suspicious, he discussed it with his relatives and realised he had been defrauded. Also Read | Fraud impersonates bizman's US-based brother, swindles ₹50k The complainant first contacted the Cyber Helpline number 1930 and filed a complaint. The Andheri police on Saturday registered a case under sections 66 (d) (dishonestly receiving stolen computer resource or communication device) of the Information Technology Act, 2000, and sections 318 (4) (cheating), 319 (2) (cheating by personation), 336 (2) and 336 (3) (forgery), 338 (forgery of valuable security documents), 340 (2) (using forged electronic document as genuine) and 61 (2) (criminal conspiracy) of the Bhartiya Nyaya Sanhita, 2023. 'We are trying to ascertain the identities of and trace the accused through the transactions made by the complainant,' said a police officer from Andheri police station.

Trump's threat spells uncertainty for exporters
Trump's threat spells uncertainty for exporters

Time of India

timean hour ago

  • Time of India

Trump's threat spells uncertainty for exporters

AP photo New Delhi: American President Donald Trump's latest announcement of a possible "substantial increase" in tariffs on Indian goods, added to the uncertainty for exporters, amid indications that govt was looking at select segments of affected industries instead of a broad-based support. To go ahead with the orders for the upcoming busy season around Christmas, tariff uncertainty is seen as the biggest issue as the buyers would compare the tariffs across countries before finalising them. In several sectors where India is competitive, including textiles and footwear, rival countries such as Bangladesh enjoy a five percentage point tariff advantage. But with the unspecified "penalty" on India for its Russian oil purchases, buyers would be unable to do the arithmetic. Besides, they would be worried about the possibility of the additional tariff coming into force over the next few months when the order is in the pipeline. As a result, they may be deterred from placing orders with Indian suppliers, many of whom they have dealt with over the years. Govt sources said that the exporters need to provide detailed analysis of the segments that will be hit by the 25% tariff. A broad-based comparison may not work as there may be other factors at play. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Learn 57+ Languages Easily with AI [Join] Talkpal AI Undo For instance, when it comes to shrimps, Ecuador is seen to be a major beneficiary of Trump's tweaked tariff announcements. But it may not have the capacity to completely replace Indian exports, estimated at over $2 billion. That's because it's a product segment where production can't be stepped up by running more machines, pointed industry and govt sources. Besides, the exporters would need to meet American standards and get the required certification, which takes time. Similarly, when it comes to textiles, not all segments will be hit equally hard. Besides, Indian players have a strong footing in some of them. For instance, when it comes to cotton T-shirts, India has a 36% share of the women's and girl's dress segment in the US. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Economic Times

timean hour ago

  • Economic Times

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store